Humacyte Inc (HUMAW)
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
Dare Bioscience Inc. (DARE)
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Dentsply Sirona Inc (XRAY)
Dentsply Sirona Reports Third Quarter 2025 Results
Solid Biosciences Inc (SLDB)
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
GeneDx Holdings (WGSWW)
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
STRATA Skin Sciences Inc (SSKN)
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
Urogen Pharma Inc (URGN)
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Vericel Corporation (VCEL)
Vericel Reports Third Quarter 2025 Financial Results
Cronos Group Inc (CRON)
Cronos Group Reports 2025 Third Quarter Results
Plus Therapeutics Inc (PSTV)
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0